XERS vs. BHVN, MTSR, ACAD, MOR, RXRX, XENE, AMRX, CPRX, HCM, and BHC
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Biohaven (BHVN), Metsera (MTSR), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry.
Xeris Biopharma vs.
Biohaven (NYSE:BHVN) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
88.8% of Biohaven shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 16.0% of Biohaven shares are held by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Xeris Biopharma had 3 more articles in the media than Biohaven. MarketBeat recorded 8 mentions for Xeris Biopharma and 5 mentions for Biohaven. Xeris Biopharma's average media sentiment score of 0.74 beat Biohaven's score of 0.59 indicating that Xeris Biopharma is being referred to more favorably in the news media.
Biohaven received 259 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 70.00% of users gave Xeris Biopharma an outperform vote while only 67.44% of users gave Biohaven an outperform vote.
Biohaven presently has a consensus price target of $63.15, suggesting a potential upside of 111.38%. Xeris Biopharma has a consensus price target of $5.92, suggesting a potential upside of 2.63%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Xeris Biopharma.
Biohaven has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500.
Xeris Biopharma has higher revenue and earnings than Biohaven. Xeris Biopharma is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Biohaven has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Biohaven's return on equity.
Summary
Biohaven and Xeris Biopharma tied by winning 9 of the 18 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:XERS) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy XERS Stock Free XERS Stock Alerts